Accelerate to discover

Back to filter

Related topics

IncuCyte white paper: live-cell analysis for Neuroscientists

Sartorius

Mar 20, 2019

Stem cell technologies using iPSCs allow researchers to create differentiated neurons and support cells to study human...

Cell plasticity associated to circulating tumor cells from prostate cancer patients

Fluxion Biosciences

Mar 13, 2019

Treatment resistance is associated with tumor cells molecular plasticity. In metastatic castration resistant prostate...

Izon qEV - The fastest & most effective Exosome isolation

IZON

Mar 6, 2019

Extracellular  vesicles  (EVs)  are  prevalent  in biological  fluids  and  are  of  great  interest  to researchers ...

Enhanced uptake of luminescent quantum dots by live cells

Etaluma

Mar 1, 2019

The steady progress made over the past threedecades in growing a variety of inorganic nanomaterials, with discreet...

Mar 21, 2019

Fat-water separation Imaging in Preclinical MRI

Bruker Biospin

Mar 1, 2019

Non-invasive in vivo phenotyping of adipose tissue deposits in small animal models is of great importance in...

Precision CellRad

Precision X-Ray

Feb 15, 2019

The CellRad system allows you to irradiate cells in your lab without compromising sterility or security. A smaller,...

New technique for dynamic monitoring of liquid tumor Cytotoxicity

Acea Biosciences

Feb 12, 2019

To develop and validate immuno-oncology therapies, scientists must understand the full dynamics of cytotoxic effectors...

Mar 21, 2019

Small animal 13C-hyperpolarized MRI

Bruker Biospin

Feb 8, 2019

13C-Hyperpolarized molecules provide a unique signature for molecular processes relevant to a range of disease...

Show all topics (10)

Preclinical cardiac safety assesment

Mar 22, 2016

Over the last two decades, a number of blockbuster drugs have been withdrawn or have incurred safety warnings by regulatory agencies due to adverse cardiac effects. In addition, lead compounds or drug candidates are frequently terminated at late stages of drug development due to cardiac safety concerns. Both of these factors can significantly impact the overall cost of drug discovery; consequently, pharmaceutical companies and regulatory agencies have implemented procedures to address these issues.

Most, if not all, in vitro assay systems for cardiac safety are designed to screen for surrogates of arrhythmia, such as hERG channel interaction, rather than arrhythmia itself. Assays designed to screen for compounds that may affect repolarization and induce arrhythmia in the context of the whole heart or heart tissue are not implemented until much later in drug development. These include sophisticated, technically demanding, lowthroughput, and costly procedures such as the Purkinje fiber assay, ventricular wedge assay, and the Langendorff whole heart assay, or telemetry experiments in live and anesthetized animals. The field of preclinical cardiac safety can certainly benefit from an assay system that allows for integrated assessment of compound action on ion channel and non-ion channel targets involved in cardiac excitation-contraction coupling.

The RTCA Cardio Instrument in conjunction with iCell Cardiomyocytes comprises an assay system providing integrated assessment of compound action on multiple targets involved in heart function. This assay system can sensitively and quantitatively detect the effect of compounds on the major ion channels involved in heart function, namely calcium, sodium, and potassium channels. Another major advantage of the assay system is the time resolution. The RTCA Cardio Instrument has a data acquisition rate of 12.5 ms per well of a 96-well plate and can be used simultaneously to monitor acute and chronic drug effects up to days and weeks. The utility of the time-dependent monitoring of compound action on cardiomyocytes can be demonstrated by testing compounds that acutely and directly block hERG channels (E4031, cisapride, etc.) and compounds that interfere with protein trafficking (pentamidine) in a sub-chronic manner. The RTCA Cardio Instrument is able to detect the effects of these compounds on the beating rate and duration of iCell Cardiomyocytes.

The xCELLigence System RTCA Cardio Instrument, in conjunction with iCell Cardiomyocytes, represents a physiologically relevant and predictive assay system for preclinical cardio-safety assessment of lead compounds. The features of this assay system, including time resolution, dynamic monitoring of mechanical beating activity of cardiomyocytes, and 96-well throughput, will surely provide additional mechanistic and toxicity information for compound action on the heart.

Application
Product news

Related technologies: Real-time, label free cell analysis

Brand profile

Acea Biosciences

ACEA manufactures xCELLigence impedance-based, label-free, real time cell analysis system and NovoCyte flow cytometers.

Related products

Cardio Instrument is a high-resolution system for label-free-dual-mode monitoring of cardiomyocyte and cardiotoxicity testing

show detail

The new CardioECR system combines impedance and Multi Electrode Array (MEA) technology with a pacing function

show detail

We supply and support Life-Science Technologies in the territory of Central and Eastern Europe.

Czech Republic

Slovakia

Hungary

Poland

Croatia

Slovenia

Serbia

Romania

Bulgaria

Latvia

Lithuania

Estonia

Russia

Ukraine

Belarus

Turkey